Collection probe and methods for the use thereof

ABSTRACT

Method and devices are provided for assessing tissue samples from a plurality of tissue sites in a subject using molecular analysis. In certain aspects, devices of the embodiments allow for the collection of liquid tissue samples and delivery of the samples for mass spectrometry analysis.

This application is a continuation of U.S. patent application Ser. No.17/106,445, filed Nov. 30, 2020, which is a continuation of U.S. patentapplication Ser. No. 16/817,728, filed Mar. 13, 2020, now U.S. Pat. No.10,943,775, which is a divisional of U.S. patent application Ser. No.15/692,167, filed Aug. 31, 2017, now U.S. Pat. No. 10,643,832, whichclaims the benefit of U.S. Provisional Patent Application Nos.62/383,234, filed Sep. 2, 2016; 62/411,321, filed Oct. 21, 2016; and62/462,524, filed Feb. 23, 2017. Each of the above-reference prioritydocuments is incorporated herein by reference in its entirety.

This invention was made with government support under Grant No. R00CA190783 awarded by the National Institutes of Health. The governmenthas certain rights in the invention.

BACKGROUND OF THE INVENTION 1. Field of the Invention

The present invention relates generally to the field of medicine,molecular biology and biochemistry. More particularly, it concernsmethods and devices for assessment of tissue samples using massspectrometry.

2. Description of Related Art

Clinical diagnosis is commonly performed through the evaluation oftissue samples pre-operatively, intra-operative, and post-operatively,at several other stages of the patient's treatment process. Tissueevaluation is very critical in the diagnosis and management of cancerpatients. Intra-operative pathologic assessment of excised tissues, forexample, is routinely performed for diagnosis and surgical marginevaluation in a variety of cancer surgeries. The resected tissuespecimens are sent to a nearby room, often called the “frozen room”, fortissue preparation, staining, and evaluation. The tissue specimen isfrozen, sectioned, stained, and interrogated using light microscopy byan expert pathologist who carefully evaluates if the surgical marginscontain cancer cells (positive margin) or not (negative margin). Whileintraoperative frozen section analysis has been performed in clinicalpractice for decades, it presents many challenges. Freezing artifactsoccur during tissue processing and interfere with tissue structure andcell morphology, thus complicating pathologic interpretation. Moreover,certain tumor cells are very difficult to recognize due to theiratypical pattern of growth and shape. Molecular approaches could providehighly accurate and potentially real-time assessments of tissue samples.However, to date adequate devices or methodologies have not beendeveloped that provide effective molecular assessment of tissue samples.

SUMMARY OF THE INVENTION

In a first embodiment there is provided a method for obtaining a massspectrometry profile comprising using a probe to apply a fixed ordiscrete volume of a solvent to an assay site (e.g., a tissue site);using the probe to collect the applied solvent to obtain a liquidsample; and subjecting the liquid sample to mass spectrometry analysis.In further embodiment a method is provided for assessing tissue samplescomprising obtaining a plurality of liquid samples from a plurality oftissue sites in a subject and subjecting the plurality of liquid samplesto mass spectrometry.

Still a further embodiment provides an apparatus for obtaining samples(e.g., from tissues) for mass spectrometry analysis, the apparatuscomprising: a chamber comprising a solvent; a pressurized gas supply; amass spectrometer; a probe comprising a reservoir, a first conduit, asecond conduit and a third conduit, wherein: the reservoir is in fluidcommunication with the first conduit, the second conduit and the thirdconduit; the first (solvent) conduit is in fluid communication with thechamber; the second (gas) conduit is in fluid communication withpressurized gas supply; and the third (collection) conduit is in fluidcommunication with the mass spectrometer. In further aspects, the massspectrometer in communication with a computer that provides a sampleanalysis. In certain aspects, the results of each sample analysis areprovided by a visual or auditory output from the computer. For example,the results of each sample analysis by the computer can be indicated bya differently colored light that is illuminated or by a differentfrequency of sound produced. In some aspects, the mass spectrometer is amobile the mass spectrometer. In further aspects, the mass spectrometercan comprise an uninterruptable power supply (e.g., a battery powersupply). In still further aspects, the mass spectrometer comprises aninlet that may be closed to keep instrument vacuum. In yet furtheraspects, the mass spectrometer is separated from the probe by a meshfilter (e.g., to block contamination).

In some aspects, the reservoir is configured to form a droplet of thesolvent. In certain aspects, the pressurized gas supply provides a gasto the probe at a pressure between 0.1 psig and 5.0 psig. In furtheraspects, the pressurized gas supply provides a gas to the probe at apressure between 0.5 psig and 2.5 psig. In several aspects, thepressurized gas supply provides air to the probe. In other aspects, thepressurized gas supply provides an inert gas such as nitrogen or carbondioxide to the probe.

In additional aspects, the apparatus further comprises a pump configuredto transfer the solvent from the chamber to the first conduit. Infurther aspects, the apparatus may comprise a first valve configured tocontrol a flow from the third conduit to the mass spectrometer. In someaspects, the third conduit is under a vacuum when the first valve is inthe open position. In other aspects, the apparatus may comprise a secondvalve configured to control a flow of pressurized gas through the secondconduit.

In certain aspects, the solvent may comprise water and/or ethanol. Inseveral aspects, the probe is formed from polydimethylsiloxane (PDMS)and/or polytetrafluoroethylene (PTFE). In some aspects, the probe isdisposable. In particular aspects, the probe may include a collectiontip that is ejectable (e.g. capable of being ejected from the probe). Infurther aspects, the probe comprises a tracking device configured totrack a location of the probe. In some aspects, the reservoir has avolume between 1 microliter and 500 microliters, between about 1microliter and 100 microliters or between about 2 microliters and 50microliters. In additional aspects, the reservoir has a volume between5.0 microliters and 20 microliters.

In still further aspects, the apparatus may additionally comprise acontrol system configured to control: a solvent flow (e.g., flow of afixed or discrete volume of solvent) from the chamber through the firstconduit to the reservoir; a pressurized gas flow from the pressurizedgas supply through the second conduit to the reservoir; and a sampleflow from the reservoir through the third conduit to the massspectrometer. In some aspects, the control system is configured to:control the solvent flow at a flow rate between 100 and 5000 microlitersper minute (e.g., between 200 and 400 microliters per minute) for aperiod of time between 1 and 3 seconds; control the pressurized gas flowat a flow rate between 1 and 10 psig for a period of time between 10 and15 seconds; and control the sample flow for a period of time between 10and 15 seconds. For example, in some aspects, the control systemcomprises a trigger or button to initiate solvent flow. In furtheraspects, the control system comprises a pedal (i.e., that can beoperated by foot action) to initiate solvent flow. A skilled artisanwill recognize that the lengths of the first and/or second conduit maybe adjusted to fit the particular use of the system. In yet furtheraspects, the control system is configured to control: a solvent flow(e.g., flow rate for a fixed period of time) from the chamber throughthe first conduit to the reservoir. In further aspects, an apparatus ofthe embodiments does not include a device for producing ultrasonic orvibrational energy (e.g., in sufficient amounts to disrupt tissues).

A further embodiment provided a method for assessing tissue samples froma subject comprising applying a solvent to a tissue site on the subject,collecting the applied solvent to obtain a liquid sample, and subjectingthe sample to mass spectrometry analysis. In certain aspects, thesolvent may be sterile. In some aspects, the solvent is pharmaceuticallyacceptable formulation. In specific aspects, the solvent is an aqueoussolution. For example, the solvent may be sterile water or consistessentially of water. In other aspects, the solvent may comprise fromabout 1% to 5%, 10%, 15%, 20%, 25% or 30% of an alcohol. In someaspects, the solvent comprises 0.1% to 20% of an alcohol, 1% to 10% ofan alcohol or 1% to 5% 1% to 10% of an alcohol (e.g., ethanol). In somecases, the alcohol may be ethanol.

In some aspects, applying the solvent to the tissue comprises applying adiscrete volume of solvent to the tissue site. In some aspect, thesolvent is applied in a single droplet. In a further aspect, the solventis applied in a discrete number of droplets from 1 to 10. In someembodiments, the solvent is applied to the sample from the reservoir viaa channel independent of the pressurized gas. In further embodiments,the solvent is applied to the sample under low pressure. For example, insome aspects, the solvent is applied by a mechanical pump such thatsolvent is applied to the tissue site (e.g., moved into a reservoirwhere it is in contact with the tissue site) with minimal force therebyexerting minimal pressure (and producing minimal damage) at a tissuesite. The low pressure may be less than 100 psig, less than 90 psig,less than 80 psig, less than 70 psig, less than 60 psig, less than 50psig, or less than 25 psig. In some embodiments, the low pressure isfrom about 0.1 psig to about 100 psig, from about 0.5 psig to about 50psig, from about 0.5 psig to about 25 psig, or from about 0.1 psig toabout 10 psig. In particular aspects, the discrete volume of solvent isbetween about 0.1 and 100 μL, or between about 1 and 50 μL. In furtheraspects, collecting the applied solvent is between 0.1 and 30 secondsafter the applying step. In a specific aspect, collecting the appliedsolvent is between 1 and 10 seconds after the applying step (e.g., atleast 1, 2, 4, 5, 6, 7, 8 or 9 seconds). In further aspects, a method ofthe embodiments does not involve application of ultrasonic orvibrational energy to a sample or tissue. In some aspects, the tissuesite in an internal tissue site that is being surgically assessed.

In a further aspect, a method of the embodiments comprises applying afixed or discrete volume of a solvent (e.g., using mechanical pump) to atissue site through a solvent conduit. In some aspects, the fixed ordiscrete volume of a solvent is moved through a solvent conduit into areservoir where it is in direct contact with a tissue site (e.g., for0.5-5.0 seconds). In further aspects, collecting the applied solventcomprises applying a negative pressure to pull the sample into acollection conduit and/or applying a gas pressure to push the sampleinto a collection conduit. In some aspects, the solvent is appliedthrough a solvent conduit that is separate from the collection conduit.In further aspects, wherein a gas pressure is applied to push the sampleinto the collection conduit the gas pressure is applied through a gasconduit that is separate from the solvent conduit and the collectionconduit. In certain aspects, wherein a gas pressure is applied to pushthe sample into the collection conduit, the applied gas pressure of lessthan 100 psig. For example, the gas pressure is preferably less than 10psig, such as 0.1 to 5 psig. In still further aspects, a method of theembodiments is defined as producing no detectable physical damage to thetissue being assessed.

In still further aspects, the method may additionally comprisecollecting a plurality liquid samples from a plurality of tissue sites.In some cases, the device (e.g., the probe) used to collect the samplesis washed between each sample collection. In other aspects, a deviceused to collect the samples includes a disposable collection tip (probe)that can be changed between each sample collection. In particularaspects, the collection tip may be ejectable (e.g. capable of beingejected from the device). In certain aspects, the plurality of tissuesites comprise 2, 3, 4, 5, 6, 7, 8, 9, 10 or more tissues sites in vivo.In another aspect, the plurality of tissue sites surround a section oftissue that has been surgically resected (e.g., ex vivo). In a specificaspect, the resected tissue is a tumor. In some aspects, the method maybe defined as an intraoperative method.

A further embodiment provides a method of identifying a sampled tissuesite and a method to communicate location of the site to the device(probe) operator. Identification of a sampled tissue site allows theoperator to access the molecular information recorded at sampled tissuesite at a time after sampling molecules collected from the tissue. Atleast three types of identification approaches are recognized. In thefirst approach, an exogenous material is attached to the sampled tissuesite that identifies the sampled molecular information. In a secondapproach, the device (probe) is equipped with a tracking sensor/emitterthat allows recording the location of the probe (device) andcommunication to an imaging device when the molecular information issampled. In a third approach, the tissue region is modified so that thesite may be easily identified after harvesting tissue molecules. In thefirst approach, materials that may be attached to the sampled tissuesite include, for example, a suture, a surgical clip, a biocompatiblepolymer that adheres to the tissue, or an RFID chip that is attached toa magnetic bead that allows easy reading and removal. In the secondapproach type, the probe may contain an RF emitter that is part of a RFsurgical tracking system, an ultrasound emitter or reflector that ispart of an intra-operative US imaging system. In this second approach,when the operator initiates collection of tissue molecules, the trackingsystem records location of the probe in the associated imaging system(e.g., RF, US, CT, MRI) that may be in communication with the device.The operator may then identify any of the sampled tissue sites at alater time by referring to the recorded image(s) that can indicate thelocation of sampled sites to the operator. In the third approach, thetissue is modified. In this third approach, a laser source incommunication with the probe may be used to ablate or coagulate apattern into the tissue that identifies the sampled site. Any of thesethree approaches may be combined. For example, approach 1, 2 and 3 couldbe combined wherein an exogenous material is attached to the tissue siteafter harvesting tissue molecules and a laser patterns the exogenoustissue while an RF sensor records location of the harvest location andcommunicates to the imaging device.

In yet still further aspects, the mass spectrometry comprises ambientionization MS. In several aspects, subjecting the sample to massspectrometry analysis may comprise determining a profile correspondingto the tissue site. In another aspect, the method may additionallycomprise comparing the profile to a reference profile to identify tissuesites that include diseased tissue. In other aspects, the method alsocomprises resecting tissue sites that are identified to include diseasedtissue. In some aspects, the method is performed using an apparatus inaccordance with any of the embodiments and aspects described above.

In a further embodiment, the invention provides an ex vivo method forassessing tissue samples comprising obtaining a plurality of liquidsamples from a plurality of tissue sites in a subject, subjecting theplurality of liquid samples to mass spectrometry to obtain a pluralityof profiles corresponding to the tissue sites, and comparing theplurality of profiles to reference profiles to identify tissue sitesthat include diseased tissue. In certain aspects, the liquid samples arecomprised in a solvent. In further aspects, the diseased tissuescomprise cancer cells.

In some aspects of the embodiments, the diseased tissue sites forassessment by methods and devices of the embodiments comprise (or aresuspected of comprising) cancer cells. Cancer cells that may be assessedaccording to the embodiments include but are not limited to cells ortumor tissues from a thyroid, lymph node, bladder, blood, bone, bonemarrow, brain, breast, colon, esophagus, gastrointestine, gum, head,kidney, liver, lung, nasopharynx, neck, ovary, prostate, skin, stomach,testis, tongue, or uterus (or tissues surrounding such tumors). In someaspects, the cancer may be a neoplasm, malignant; carcinoma; carcinoma,undifferentiated; giant and spindle cell carcinoma; small cellcarcinoma; papillary carcinoma; squamous cell carcinoma;lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma;transitional cell carcinoma; papillary transitional cell carcinoma;adenocarcinoma; gastrinoma, malignant; cholangiocarcinoma;hepatocellular carcinoma; combined hepatocellular carcinoma andcholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma;adenocarcinoma in adenomatous polyp; adenocarcinoma, familial polyposiscoli; solid carcinoma; carcinoid tumor, malignant; branchiolo-alveolaradenocarcinoma; papillary adenocarcinoma; chromophobe carcinoma;acidophil carcinoma; oxyphilic adenocarcinoma; basophil carcinoma; clearcell adenocarcinoma; granular cell carcinoma; follicular adenocarcinoma;papillary and follicular adenocarcinoma; nonencapsulating sclerosingcarcinoma; adrenal cortical carcinoma; endometroid carcinoma; skinappendage carcinoma; apocrine adenocarcinoma; sebaceous adenocarcinoma;ceruminous adenocarcinoma; mucoepidermoid carcinoma; cystadenocarcinoma;papillary cystadenocarcinoma; papillary serous cystadenocarcinoma;mucinous cystadenocarcinoma; mucinous adenocarcinoma; signet ring cellcarcinoma; infiltrating duct carcinoma; medullary carcinoma; lobularcarcinoma; inflammatory carcinoma; paget's disease, mammary; acinar cellcarcinoma; adenosquamous carcinoma; adenocarcinoma w/squamousmetaplasia; thymoma, malignant; ovarian stromal tumor, malignant;thecoma, malignant; granulosa cell tumor, malignant; androblastoma,malignant; sertoli cell carcinoma; leydig cell tumor, malignant; lipidcell tumor, malignant; paraganglioma, malignant; extra-mammaryparaganglioma, malignant; pheochromocytoma; glomangiosarcoma; malignantmelanoma; amelanotic melanoma; superficial spreading melanoma; maligmelanoma in giant pigmented nevus; epithelioid cell melanoma; bluenevus, malignant; sarcoma; fibrosarcoma; fibrous histiocytoma,malignant; myxosarcoma; liposarcoma; leiomyosarcoma; rhabdomyosarcoma;embryonal rhabdomyosarcoma; alveolar rhabdomyosarcoma; stromal sarcoma;mixed tumor, malignant; mullerian mixed tumor; nephroblastoma;hepatoblastoma; carcinosarcoma; mesenchymoma, malignant; brenner tumor,malignant; phyllodes tumor, malignant; synovial sarcoma; mesothelioma,malignant; dysgerminoma; embryonal carcinoma; teratoma, malignant;struma ovarii, malignant; choriocarcinoma; mesonephroma, malignant;hemangiosarcoma; hemangioendothelioma, malignant; kaposi's sarcoma;hemangiopericytoma, malignant; lymphangiosarcoma; osteosarcoma;juxtacortical osteosarcoma; chondrosarcoma; chondroblastoma, malignant;mesenchymal chondrosarcoma; giant cell tumor of bone; ewing's sarcoma;odontogenic tumor, malignant; ameloblastic odontosarcoma; ameloblastoma,malignant; ameloblastic fibrosarcoma; pinealoma, malignant; chordoma;glioma, malignant; ependymoma; astrocytoma; protoplasmic astrocytoma;fibrillary astrocytoma; astroblastoma; glioblastoma; oligodendroglioma;oligodendroblastoma; primitive neuroectodermal; cerebellar sarcoma;ganglioneuroblastoma; neuroblastoma; retinoblastoma; olfactoryneurogenic tumor; meningioma, malignant; neurofibrosarcoma;neurilemmoma, malignant; granular cell tumor, malignant; malignantlymphoma; hodgkin's disease; hodgkin's; or paragranuloma. In furtheraspects the cancer is a thyroid cancer, brain cancer (e.g., a glioma), aprostate cancer, a breast cancer (e.g., a triple negative breastcancer), a pancreatic cancer (e.g., a pancreatic ductal adenocarcinoma),acute myeloid leukemia (AML), melanoma, renal cell cancer or a cancerthat has metastasized to a lymph node.

As used herein, “sample” or “liquid samples” can refer to extracts fromtissues or other biological specimens (e.g., extracts comprisingproteins and metabolites) obtained by contacting tissue or biologicalspecimen with a solvent according to the embodiments. In some aspects, asample can be an extract from a non-biological specimen, such as thesurface on an object (e.g., a forensic sample).

As used herein, “essentially free,” in terms of a specified component,is used herein to mean that none of the specified components has beenpurposefully formulated into a composition and/or is present only as acontaminant or in trace amounts. The total amount of the specifiedcomponent resulting from any unintended contamination of a compositionis therefore well below 0.01%. Most preferred is a composition in whichno amount of the specified component can be detected with standardanalytical methods.

As used herein in the specification and claims, “a” or “an” may mean oneor more. As used herein in the specification and claims, when used inconjunction with the word “comprising”, the words “a” or “an” may meanone or more than one. As used herein, in the specification and claim,“another” or “a further” may mean at least a second or more.

As used herein in the specification and claims, the terms “conduit” and“tube” are used interchangeably and refer to a structure that can beused to direct flow of a gas or liquid.

As used herein in the specification and claims, the term “about” is usedto indicate that a value includes the inherent variation of error forthe device, the method being employed to determine the value, or thevariation that exists among the study subjects.

Other objects, features and advantages of the present invention willbecome apparent from the following detailed description. It should beunderstood, however, that the detailed description and the specificexamples, while indicating certain embodiments of the invention, aregiven by way of illustration only, since various changes andmodifications within the spirit and scope of the invention will becomeapparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and areincluded to further demonstrate certain aspects of the presentinvention. The invention may be better understood by reference to one ormore of these drawings in combination with the detailed description ofspecific embodiments presented herein.

FIG. 1A-Q: Schematic representation of the MasSpec Pen system andoperational steps. A) The pen-sized handheld device is directlyintegrated into lab-built mass spectrometer interface through PTFEtubing (or another highly hydrophobic material). The interface housesthe pinch valves, microcontroller, and tubing to connect the system tothe mass spectrometer inlet. The system is automatically triggered bythe user through a foot pedal. B) The MasSpec Pen is designed with aPDMS 3D-printed tip and three PTFE conduits, which provide incomingwater to the tip, gas, and an outgoing conduit for the water droplet. C)The tip contacts the tissue for analysis, and it designed with 3conduits and a solvent reservoir. When the system is triggered (t=0 sec)by the use through the pedal, the syringe pump delivers a controlledvolume of water to the reservoir. The discrete water droplet interactswith the tissue to extract molecules. After, in this case, 3 seconds ofextraction, the vacuum and the gas conduits are concommintantly openedto transport the droplet from the MasSpec Pen to the mass spectrometerthrough the tubing system for molecular analysis. D) Show a schematic ofthe exemplary functional element of a MasSpec Pen device. E-F) Showenlarged views of the tip of an exemplary MasSpec Pen. G-Q) Showalternative configurations of a system of the embodiments.

FIGS. 2A-2B: Mass spectra of mouse brain tissue section from MasSpec Penusing Q Exactive Orbitrap Mass Spectrometer. A) Mass spectrum of mousebrain section, B) Total ion chromatography, the inset spectrum is fromthe clean glass slide background (the intensity scale of the backgroundand mouse brain tissue were set to be the same).

FIGS. 3A-3B: A) Shows a comparison of mass spectra of biological samplesthat was obtained using a solvent composed of ethanol:H₂O (1:20) orethanol:H₂O (1:5). B) Representative negative ion mode MasSpec Pen massspectra obtained from mouse brain tissue sections using mixtures ofwater and ethanol at various ratios.

FIGS. 4A-4B: Comparison of mass spectra using MasSpec Pen collected froma) mouse brain sections and b) mouse brain fresh tissue.

FIG. 5A-E: Comparison of mass spectra in cancer versus normal tissue fora variety of different cancer types: breast cancer (A); kidney cancer(B); a cancerous lymph node (C) ovarian cancer (D) and thyroid cancer(E).

FIGS. 6A-6C: Comparison of mass spectra collected from A) MasSpec Penand B) DESI. C) Comparison between MasSpec Pen and DESI negative ionmode mass spectra obtained from a mouse brain tissue section.

FIG. 7 : The spectrum of thymosin β-4 which detected in human tissuesunder negative ion mode.

FIGS. 8A-8B: A) Comparison of spectra which were obtained from freshthyroid normal and cancer specimens. B) MasSpec Pen analysis ofpapillary thyroid carcinoma and normal tissue sections. (top) Arepresentative negative ion mode MasSpec Pen mass spectra obtained froma normal thyroid tissue section, and (bottom) a papillary thyroidcarcinoma tissue section are shown. Identification of the most abundantmolecular ions are provided. Insets shows an optical image of the H&Estained tissue section evaluated by histopathology.

FIG. 9 : PCA of the data obtained for the human tissue sectionsincluding normal and tumor thyroid and breast tissue sections. Asobserved in the scores plots, PC1 and PC3 explain 46.1% of the totalvariance of the breast tissue dataset, while PC1 and PC2 explain 47.9%of the total variance of the thyroid tissue dataset. Loading plots arealso included for each tissue type analyzed.

FIGS. 10A-10B: Principal component analysis results for human freshtissues. A) Discrimination of normal and tumorous thyroid. B)Discrimination of normal and tumorous lymph nodes.

FIG. 11 : The molecular information obtained from tissue samples usingthe MasSpec Pen is diagnostic of human cancer. A total of 253 patienttissue samples were analyzed including breast, thyroid, ovary and lungcancer and normal tissue samples. 3D PCA (PC1, PC2 and PC3) plots showsseparation between cancer and normal mass spectra obtained.

FIGS. 12A-12E: Mapping of the Sample Spot 1 (FIG. 12A), Sample Spot 2(FIG. 12B), Sample Spot 3 (FIG. 12C), Sample Spot 4 (FIG. 12D), andSample Spot 5 (FIG. 12E).

FIGS. 13A-13E: Mass Spectrum of Sample Spots 1-5 at full mass range(FIG. 13A), 500-1800 mass range (FIG. 13B), 500-1000 mass range (FIG.13C), 785 to 809 mass range (FIG. 13D), and 870 to 920 mass range (FIG.13E).

FIGS. 14A-14C: MasSpec Pen analysis of a HGSC tissue sample with mixedhistologic composition. A) Optical image shows the tissue sample whichwas analyzed at the demarcated spots (1-5) using a 1.5 mm diameterMasSpec Pen. After MasSpec Pen analysis, the tissue sample was frozen,sectioned and H&E stained. An optical image of H&E stained tissuesection obtained at spot 3 is shown, presenting mixed histologiccomposition including cancer and adjacent normal stroma tissue. B) TheMasSpec Pen negative ion mode mass spectra is shown for spot 1 (normalstroma), spot 3 (mixture of normal stroma and cancer), and spot 5(cancer). C) Pathologic diagnosis of the five spots analyzed and Lassoprediction results for this independent set of data are shown.

FIGS. 15A-15B: The MasSpec Pen allows gentle and non-destructivemolecular analysis of tissue samples. A) Optical images show a lungadenocancinoma tissue sample before, during and after MasSpec Penanalysis. A magnification of the tissue specimen shows no macroscopicdamage to the tissue region analyzed by the MasSpec Pen. B) The negativeion mode mass spectrum obtained for the tissue region analyzed is shownincluding identification of the most abundant molecular ions.

FIGS. 16A-16B: In vivo analysis of tumor and normal tissues duringsurgery on a murine animal model. A) Experiments were performed on miceunder anesthesia. Optical images show the animal and in vivo before,during, and after MasSpec Pen analysis. B) Representative negative ionmode mass spectra show distinct molecular profiles from normal and tumortissues.

FIG. 17 : Representative negative ion mode MasSpec Pen mass spectraobtained using various sampling diameters of the MasSpec Pen.

FIG. 18 : Representative positive ion mode mass spectra from mouse braintissue. Ions observed at high relative abundances were identified usingtandem mass spectrometry as potassium (K+) and sodium (Na+) adducts ofglycerophosphocholines and diacylglycerides lipids, as annotated in themass spectra.

FIG. 19 : Representative negative ion mode MasSpec Pen mass spectraobtained from a HGSC tissue sample containing regions of normal andcancer tissues.

FIG. 20 : Optical image of the in vivo analysis after and the H&Estained tissue section obtained from the same region after MasSpec Penanalysis.

FIG. 21 : Comparison between the MasSpec Pen negative ion mode massspectra obtained in vivo and ex vivo of the same tumor sample from mousemodel.

FIG. 22 : Representative negative ion mode mass spectra obtained from amouse brain tissue sections with different extraction times, 5 seconds,3 seconds, and 1 second.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS I. The Present Embodiments

In certain aspects, the instant application provides methods and devicesfor molecular assessment of samples, such as tissue samples. Inparticular, aspects the methods can be used to assess multiple tissuesites during an operation (or biopsy) of the tissue. This feature allowsfor accurate identification of diseased tissues (e.g., tissue sitesretaining cancer cells) in “real-time” allowing surgeons to moreaccurately address only the diseased tissue relative to surroundingnormal tissues. In particular aspects, the methods disclosed here caninvolve delivery of a fixed or discrete volume of solvent to a tissuesite, followed by collection of a liquid sample from the site andanalysis of the liquid sample by mass spectrometry. Importantly, ratherthan being applied in a high pressure spray, solvent is applied asdiscreet droplets and at low pressure. These methods allow for accuratecollection of samples from a distinct tissue site while avoiding damageto the tissue being assessed. The resulting mass spectrometry profilefrom collected samples allows for differentiation of diseased versusnormal tissue sites. The method can be repeated at multiple sites ofinterest to very accurately map molecular changes (e.g., in a tissue).Importantly, the profiles of samples could be differentiated evenwith-out the use an ionization source. Thus, while methods of theembodiments could be used in conjunction with an ionization source, theuse of such a source is not required. These methodologies can allowassessment of plurality of tissue sites over a short range of time,thereby allowing for very accurate assessment of the boundaries ofdiseased versus normal tissues.

In some aspects, the methods detailed herein can be used to collect andanalyze samples from a wide range of sources. For example, the methodscan be used to assess forensic, agriculture, drug of abuse,pharmaceutical, and/or oil/petroleum samples.

In some aspects, the materials (PDMS and PTFE) and solvent (e.g., wateronly solvents) used in the devices of the embodiments are biologicallycompatible, such that they can be used in surgery in for real-timeanalysis. Furthermore, because the devices can be very compact, it canbe hand-held or integrated to a robotic surgical system, such as the DaVinci surgical system (e.g., in an automated system). Thus, many regionsof the human body cavity can be quickly sampled during surgery, andanalyzed (e.g., by using a database of molecular signatures and machinelearning algorithms). Therefore, the diagnostic results may be providedin real time for each sampled region. Exemplary devices for use in thesemethods are detailed below.

Referring initially to FIG. 1D, an apparatus 100 is shown for samplingtissue for mass spectrometry analysis. In this embodiment, apparatus 100comprises a probe 110, a chamber 120 with solvent, a pressurized gassupply 130 and a mass spectrometer 140. In some aspects, the probe iscomprised in housing (e.g., to provide a grip in the case of a hand-helddevice). In further aspects, the housing can comprise clicker feature(e.g., a trigger, button or pedal) that can be used to control fluidand/or gas flow through the probe. In some aspects, the probe iscomposed of a material comprising PDMS and/or PTFE. In some aspects, theprobe is produced by a 3D printing process.

FIG. 1E provides a more detailed cross-section view of probe 110 andillustrates probe 110 comprises a first conduit 111, a second conduit112, a third conduit 113 and a reservoir 115. In the illustratedembodiment, first conduit 111 is in fluid communication with chamber120, second conduit 112 is in fluid communication with pressurized gassupply 130, and third conduit 113 is in fluid communication with massspectrometer 140. FIG. 1F provides an additional cross-section view of aprobe with dimensions for a particular embodiment.

It is understood that in certain embodiments, each of conduits 111, 112and 113 (which can be of any desired length) may comprise separatecomponents. For example, the portion of each of the conduits withinprobe 110 may be formed as integral channels during the manufacturing ofprobe 110. In addition, the portions of each of the conduits betweenprobe 110 and chamber 120, pressurized gas supply 130 and massspectrometer 140 may be tubing or other components suitable forproviding fluid flow.

In this embodiment, apparatus 100 may comprise a pump 125 configured totransfer the solvent from chamber 120 to the first conduit 111 andreservoir 115. In the embodiment shown, apparatus 100 can also comprisea first valve 121 configured to control a sample flow from reservoir 115through third conduit 113 to mass spectrometer 140. Apparatus 100 canalso comprise a second valve 122 configured to control a flow ofpressurized gas through second conduit 112 to reservoir 115.

A control system 160 can be configured to control operating parametersof apparatus 100. For example, control system 160 can be configured tocontrol a flow of solvent from chamber 120 through first conduit 111 toreservoir 115 by controlling the operation of pump 125. In addition,control system 160 can be configured to control the sample flow fromreservoir 115 to mass spectrometer 140 by controlling the opening andclosing of first valve 121. Control system 160 can further be configuredto control the pressurized gas flow from pressurized gas container 130to reservoir 115 by controlling the opening and closing of second valve122.

During operation of apparatus 100, a user can position probe 110 so thatreservoir 115 is placed on sample site 150. Control system 160 canoperate pump 125 for specific periods of time to transfer a desiredvolume of the solvent from chamber 120 to reservoir 115 via firstconduit 111. In exemplary embodiments, the solvent in chamber 120 canassist in the efficient extraction of molecules from a tissue samplesite 150 for analysis.

In addition, control system 160 can allow a particular period of timebetween the operation of pump 125 and the opening of first valve 121.This can allow a vacuum from mass spectrometer 140 (or a separate,auxiliary vacuum system) to draw sample materials (e.g. molecules fromtissue sample site 150) from reservoir 115 to mass spectrometer 140 viathird conduit 113.

When first valve 121 is opened, control system 160 can also open secondvalve 122 to allow an inert gas (e.g. N₂ or CO₂) to be transferred frompressurized gas supply 130 to reservoir 115 via second conduit 112. Theinert gas can assist in sample tissue drying prior to analysis, as wellas prevent a solvent gap in first conduit 111 (e.g. as a result of avacuum pulled by mass spectrometer 140 when reservoir 115 contactssample site 150). The inert gas can also assist in solvent transportfrom sample site 150 to mass spectrometer 140 through third conduit 113.

Control system 160 may comprise software and hardware suitable foroperating the various components of apparatus 100. Particularembodiments of the various components shown in the schematic of FIG. 1are provided in the examples discussed below, including the sectionentitled Example 1.

FIG. 1G illustrates an embodiment of apparatus 100 that is similar tothe embodiment shown in the previous FIG. 1D. In the embodiment of FIG.1G, however, apparatus 100 further comprises a pump 141 in fluidcommunication with conduit 113. In certain embodiments, pump 141 may bean external vacuum pump that can be operated to increase the velocity ofthe sample portion through conduit 113 to the mass spectrometer. It isunderstood that the components of apparatus 100 described in previousembodiments operate in an equivalent manner in this embodiment (andsubsequently described embodiments). For purposes of clarity, not allcomponents are labeled with reference numbers in each of the figures. Inaddition, the operational aspects of components that are equivalent tocomponents in previously-described embodiments will not be repeated inthe discussion of this or subsequent embodiments.

FIG. 1H illustrates another embodiment of apparatus 100 that is similarto the previously-described embodiments but also comprises a valve 142,a waste container 143 and a pump 144 in fluid communication with conduit113. In certain embodiments, valve 142 may be used to diverge a solventor other cleaning solution from conduit 113 to waste container 143during cleaning steps. Waste container 143 can be emptied via operationof pump 144. In exemplary embodiments, cleaning or washing steps usingwater, ethanol, mixtures of water and ethanol at any ratio, as well asother solvent may be used at any stage of sample analysis to decreasecarry over effects. In certain embodiments, probe 110 may also beswitched between each use. Further, probe 110 may be inserted into avial containing solvent for washing step using gas (bubbling) to assistwith cleaning before or after the automatic wash step. Other cleaningmethods including wiping with a sterile solution may also be used. Forexample, certain embodiments may use a cleaning protocol of: 1. Replaceprobe; 2. Wash with solution of 50/50 ethanol/water; 3. Wash with 100%ethanol.

FIG. 1I illustrates another embodiment of apparatus 100 that is similarto the previously-described embodiments but also comprises a heatingelement 145 on conduit 113. In certain embodiments, heating element 145is configured as a heating wire that may be wrapped around conduit 113.In other embodiments may comprise different heating elementconfigurations, including for example, ceramic heaters. Conduit 113 maybe heated to improve water or solvent transport to mass spectrometer140, as well as to assist in ionization, in any of the exemplaryembodiments described herein. Heating can be implemented through theentire conduit system or at specific locations.

FIG. 1J illustrates an embodiment of apparatus 100 that combinesfeatures of previously-described embodiments. In particular, theembodiment shown in this figure includes heating element 145 on conduit113 and pump 141. The operational aspects of heating element 145 andpump 141 have been previously discussed in the description of FIGS. 1Iand 1G, respectively, and will not be repeated here for the sake ofbrevity.

FIG. 1K illustrates an embodiment of apparatus 100 that is similar tothe previously-described embodiments but also comprises an ionizationdevice 146 to form a spray in proximal to an inlet for mass spectrometer140. In certain embodiments, ionization device 146 may be, for example,an electrospray ionization (ESI) device, a nano ESI device, or anatmospheric pressure chemical ionization (APCI) device. In particularembodiments, conduit 113 is not directly connected to mass spectrometer140 and a venturi device 147 can be used to transport a droplet ofsample 150 to ionization device 146 and the interface of massspectrometer 140. A mass spectrometry profile is shown in FIG. 1L of anembodiment of apparatus 100 including a venturi device. As shown in FIG.1L, the profile obtained is similar to embodiments directly couplingconduit 113 to the inlet of mass spectrometer 140.

Referring now to FIG. 1M, an embodiment of apparatus 100 includesexternal pump 141 (as previously shown and described in FIG. 1G) andionization device 146 and venturi device 147 as shown (as previouslyshown and described in FIG. 1K).

As shown in the embodiment of FIG. 1N, an embodiment of apparatus 100includes heating element 145 (as previously shown and described in FIG.1I) and ionization device 146 and venturi device 147 as shown (aspreviously shown and described in FIG. 1K).

As shown in the embodiment of FIG. 1O, an embodiment of apparatus 100includes heating element 145 (as previously shown and described in FIG.1I) and ionization device 146 and venturi device 147 as shown (aspreviously shown and described in FIG. 1K). In addition, this embodimentalso includes external pump 141 (as previously shown and described inFIG. 1G).

As shown in the embodiment of FIG. 1P, an embodiment of apparatus 100includes valve 142, waste container 143 and pump 144 (as previouslyshown and described in FIG. 1H). In addition, this embodiment alsoincludes ionization device 146 and venturi device 147 as shown (aspreviously shown and described in FIG. 1K).

As shown in the embodiment of FIG. 1Q, an embodiment of apparatus 100includes valve 142, waste container 143 and pump 144 (as previouslyshown and described in FIG. 1H). In addition, this embodiment alsoincludes ionization device 146 and venturi device 147 as shown (aspreviously shown and described in FIG. 1K). This embodiment furtherincludes heating element 145 (as previously shown and described in FIG.1I).

II. Assay Methodologies

In some aspects, the present disclosure provides methods of determiningthe presence of diseased tissue (e.g., tumor tissue) or detecting amolecular signature of a biological specimen by identifying specificpatterns of a mass spectrometry profile. Biological specimens foranalysis can be from animals, plants or any material (living ornon-living) that has been in contact with biological molecules ororganisms. A biological specimen can be samples in vivo (e.g. duringsurgery) or ex vivo.

A profile obtained by the methods of the embodiments can correspond to,for example, proteins, metabolites, or lipids from analyzed biologicalspecimens or tissue sites. These patterns may be determined by measuringthe presence of specific ions using mass spectrometry. Some non-limitingexamples of ionizations methods that can be coupled to this deviceinclude chemical ionization, laser ionization, atmospheric-pressurechemical ionization, electron ionization, fast atom bombardment,electrospray ionization, thermal ionization. Additional ionizationmethods include inductively coupled plasma sources, photoionization,glow discharge, field desorption, thermospray, desorption/ionization onsilicon, direct analysis in real time, secondary ion mass spectroscopy,spark ionization, and thermal ionization.

In particular, the present methods may be applied or coupled to anambient ionization source or method for obtaining the mass spectral datasuch as extraction ambient ionization source. Extraction ambientionization sources are methods with, in this case, liquid extractionprocesses dynamically followed by ionization. Some non-limiting examplesof extraction ambient ionization sources include air flow-assisteddesorption electrospray ionization (AFADESI), direct analysis in realtime (DART), desorption electrospray ionization (DESI), desorptionionization by charge exchange (DICE), electrode-assisted desorptionelectrospray ionization (EADESI), electrospray laser desorptionionization (ELDI), electrostatic spray ionization (ESTASI), Jetdesorption electrospray ionization (JeDI), laser assisted desorptionelectrospray ionization (LADESI), laser desorption electrosprayionization (LDESI), matrix-assisted laser desorption electrosprayionization (MALDESI), nanospray desorption electrospray ionization(nano-DESI), or transmission mode desorption electrospray ionization(TM-DESI).

As with many mass spectrometry methods, ionization efficiency can beoptimized by modifying the collection or solvent conditions such as thesolvent components, the pH, the gas flow rates, the applied voltage, andother aspects which affect ionization of the sample solution. Inparticular, the present methods contemplate the use of a solvent orsolution which is compatible with human issue. Some non-limitingexamples of solvent which may be used as the ionization solvent includewater, ethanol, methanol, acetonitrile, dimethylformamide, an acid, or amixture thereof. In some embodiments, the method contemplates a mixtureof acetonitrile and dimethylformamide. The amounts of acetonitrile anddimethylformamide may be varied to enhance the extraction of theanalytes from the sample as well as increase the ionization andvolatility of the sample. In some embodiments, the composition containsfrom about 5:1 (v/v) dimethylformamide:acetonitrile to about 1:5 (v/v)dimethylformamide:acetonitrile such as 1:1 (v/v)dimethylformamide:acetonitrile. However, in preferred embodiment thesolvent for use according to the embodiments is a pharmaceuticallyacceptable solvent, such as sterile water or a buffered aqueoussolution.

III. Examples

The following examples are included to demonstrate preferred embodimentsof the invention. It should be appreciated by those of skill in the artthat the techniques disclosed in the examples which follow representtechniques discovered by the inventor to function well in the practiceof the invention, and thus can be considered to constitute preferredmodes for its practice. However, those of skill in the art should, inlight of the present disclosure, appreciate that many changes can bemade in the specific embodiments which are disclosed and still obtain alike or similar result without departing from the spirit and scope ofthe invention.

Example 1—Smart MasSpec Pen Design

The MasSpec Pen (FIG. 1A) was developed as an automated andbiocompatible handheld sampling probe that allows gentle, time- andvolume-controlled extraction of molecules from a tissue sample using adiscrete water droplet. Several prototypes of the system were engineeredwith the goal of minimizing tissue damage, maximizing tissue-analyteextraction, and maximizing solvent transfer to the mass spectrometer.

The system developed consists of three main parts: 1) a syringe pumpthat is programmed to deliver a discrete solvent volume using acontrolled flow rate; 2) tubing systems integrated to two-way pinchvalves for controlled solvent transport; 3) a probe tip which is usedfor direct sampling of biological tissues. Several iterations of thesystem were explored and optimized with the ultimate goal of minimizingtissue damage, maximizing tissue-analyte extraction, and maximizingsolvent transmission to the mass spectrometer. FIG. 1A shows a schematicfigure of one example of an apparatus comprising a Diagnostic Pen(MasSpec Pen) device for analyzing biological tissue.

The optimized system contains three primary components: 1) a syringepump that is programmed to deliver a defined water volume (4-10 μL) tothe sampling probe; 2) small diameter (ID 800 μm)polytetrafluoroethylene (PTFE) tubing conduits which are integrated to afast (8 ms) two-way pinch valves for controlled solvent transport frompump to tissue, and from the tissue to the mass spectrometer; 3) ahandheld pen-sized probe for direct sampling of biological tissues.

The main component of the handheld pen-sized probe is a 3D-printedpolydimethylsiloxane (PDMS) tip (FIG. 1B) in which the solvent isretained during interaction with the tissue. The tip was manufacturedusing 3D-printing and is made of biologically compatiblepolydimethylsiloxane (PDMS). The tip is designed with three main ports:one for the incoming (solvent) conduit system (tube 111 or conduit 1), acentral port for gas (N₂, CO₂ or air) delivery (tube 112 or conduit 2),and an outgoing port to transport molecular constituents in the waterdroplet from tissue to the mass spectrometer (tube 113 or conduit 3). Atthe probe tip, all ports combine into a small reservoir where the singledroplet is retained and exposed to the tissue sample for a controlledamount of time (3 s), allowing efficient analyte extraction. Thediameter of the reservoir determines the volume of solvent exposed tothe tissue as well as the spatial resolution of the device. Usingcurrent tooling, MasSpec Pen tips were designed with sampling sizesranging from 1.5 mm to 5.0 mm, which is determined by the reservoirdiameter. At a 2.77 mm reservoir diameter, a solvent volume of 10 μL isretained in the reservoir and contacted to the tissue sample for adefined time period, while 4.4 μL are retained in a reservoir with a 1.5mm diameter. After the 3 s extraction period, the MasSpec Pen is removedfrom the tissue. Concomitantly, conduit 3 is opened allowing vacuumextraction of the droplet to the mass spectrometer, a positive pressurefrom a low-pressure gas delivery (<10 psi) is provided through conduit2, followed by a flush step to clean the system. Note that contact timesof 1 second, 3 seconds and 5 seconds between the droplet and the tissuesample were evaluated (FIG. 22 ). The 3 seconds contact time wasselected for all the experiments as it allowed ease of operation by theuser and yielded mass spectra with sufficient total ion intensity. Thegas provided by the second tube does not participate in the extractionprocess, but is used instead to prevent collapse of the system due tothe vacuum employed and to assist solvent transport from tissue to themass spectrometer. Similarly, the flush step is not used for extractionof biomolecules from tissues as there is no contact with tissue duringthis period. Conduit 3 is directly connected to the transfer tube of ahigh mass-resolution Orbitrap mass spectrometer so that the negativepressure of the mass spectrometer vacuum system drives movement of thedroplet from the reservoir to the mass spectrometer for ionization andmass analysis. This set up simplifies the operational steps andprecludes the use of ionization sources, although various connection andionization methods could be coupled to our system. A tube length of 1.5meters was employed for all the conduits to allow free handheld use ofthe device by an operator without geometrical or spatial constraints.

The three conduit tubes used are made of polytetrafluoroethylene (PTFE),which is also biologically compatible. Tube 111 is used to deliversolvent from syringe pump to the probe tip. Tube 112 is used, in somecases, to deliver an inert gas (N₂ or CO₂) to the probe tip. The gasserves three main purposes: 1) tissue drying prior to analysis; 2)prevent solvent gap in tube 111 due to the mass spectrometer's vacuumwhen the reservoir is closed by contacting the tissue specimen; 2)assist solvent transport from tissue to the mass spectrometer throughtube 113. However, in some circumstances there is no need for use of agas. Tube 113 is directly connected to the inlet of the massspectrometer so that the positive pressure of the mass spectrometervacuum system is used to drive the droplet from the reservoir to themass spectrometer inlet for ionization.

The time events involved in the device operation are automated andprecisely controlled by software that communicates with an Arduinosystem and two two-way pinch valves. All pinch valves are closed untilthe process is initiated when: 1. under 300 μL/min, a pulse is sent tothe pump to infuse the solvent for two seconds and stop, generating a 10μL droplet filling in the MasSpec Pen reservoir; 2. Tubes 112 and 113are closed, allowing the solvent in the reservoir to interact with thetissue for three seconds to extract the molecules; 3. The pinch valvescontrolling tubes 112 and 113 are opened simultaneously, allowing thedroplet to transfer to the mass spectrometer for ionization andmolecular analysis. 4. A pulse is sent to the pump to infuse the solventfor another 12 seconds and stop, to completely drive all the extractedmolecules into the mass spectrometer. 5. Leave tube 112 and 113 open foranother 20 seconds to allow all the solvent in tube 113 to go into themass spectrometry. The total analyzing time is 37 seconds.

The tip design using three conduit tubes and high speed actuated pinchvalves allowed precise control of droplet motion and showed excellentperformance and robustness. The entire process from sampling to massspectral acquisition is completed in 10 s or less and is fully automatedusing an Arduino microcontroller, so that each acquisition and analysisis individually triggered through a one-step click using a foot pedal.System automation ensures that each solvent droplet is deliveredseparately to the inlet, yielding several mass spectra that are averagedfor a final molecular profile of the sample. Further, controlled dropletdelivery allowed the mass spectrometer to operate without any evidentperformance degradation. After each use, the MasSpec Pen can be cleanedif residues are observed through a rapid and automated cleaning flush,or by replacing the disposable tip.

Example 2—Molecular Profiles and Analysis

The system described herein operates by directly connecting thecollection conduit to the mass spectrometer inlet for transporting theanalyte-containing solvents to the mass spectrometer for molecularanalysis. This set up greatly simplifies operational details andprecludes the use of ionization sources. After the probe interacts withthe tissue, the solvent is then transported to the mass spectrometer anddirectly infused without the need of an additional ionization source.Since the system is fully automated so that each 10 μL solvent dropletis delivered separately to the inlet, the mass spectrometer operateswithout any impact on its performance. Rich molecular information isobtained in this manner, similar to what is observed from othersolvent-extraction ambient ionization techniques such as desorptionelectrospray ionization. The ionization mechanism may be similar toinlet ionization. For inlet ionization methods, the ionization occurs inthe inlet pressure drop region between atmosphere and vacuum. Severalsolvent systems can be used in the device. In this example, to assurefull biological compatibility of the device, water was used as the onlysolvent, although mixtures of ethanol and water in different ratios werealso explored and yielded similar results. To demonstrate these sampleswere analyzed after extraction with a solvent composed of 5:1 and 20:1(H₂O:EtOH) and found out EtOH will help extract more PE lipids, like PE(40:6) (m/z 790.539) and PE (38:4) (m/z 766.540) (see results in FIG. 3).

The effectiveness of the MasSpec Pen in obtaining molecular informationwas tested by analyzing thin tissue sections and pieces of tissuesamples. First, 16 μm thick tissue sections were analyzed on standardhistologic glass slides following the automated operational stepsdescribed above for the MasSpec Pen, using pure water as the solvent.Several probe tips with different reservoir diameters of the MasSpec Penwere tested, yielding mass spectra presenting lipids speciescharacteristic of mouse brain tissue grey matter, white matter, or mixedcomposition for larger sampling sizes. FIG. 2 shows a representativemass spectra obtained in the negative ion mode using a 2.7 mm pen tipfrom the grey matter region of a mouse brain tissue section, and arepresentative background mass spectra obtained from a region of glassslide (no sample). Several diameters of the MasSpec Pen were tested,yielding similar mass spectra profiles with increasing total ion countobserved for larger pen tip diameters (FIG. 17 ).

FIG. 2B shows the total ion chromatogram obtained during the totalanalysis period. At 0.5 min (see inset in FIG. 2B), the background massspectrum was acquired by contacting pure glass. As seen in the massspectrum, a remarkably clean background signal was obtained at this massrange. At 3.4 min (FIG. 2A), the MasSpec Pen was applied to a mousebrain tissue section following the same procedures discussed above.Remarkably, rich molecular profiles were observed. Lipid signalscommonly detected using ambient ionization mass spectrometry ofbiological tissues were observed at high relative intensities in thenegative ion mode mass spectrum, including fatty acids (FA), ceramides(Cer), glycerophosphoinositols (PI), glycerophosphoethanolamines (PE),glycerophosphoserines (PS) and sterol lipids (ST). Primary and secondaryendogenous metabolites were also observed in the mass spectra. In thepositive ion mode, diradylglycerols (DG), glycerophosphocholine (PC) andphosphosphingolipids (SM) were also detected. High resolving powder massanalyzer (resolving power was set as 140,000) were utilized to identifymost of the lipids in the spectrum.

The negative ion mode mass spectra obtained from the grey matter regionof the mouse brain tissue section presented rich molecular informationincluding a variety of ions corresponding to deprotonated or chlorideadducts of lipid species commonly detected from biological tissues usingsolvent-based ambient ionization MS techniques. Peaks at high relativeabundancies were identified as fatty acids (FA) from m/z 120-350,sphingolipids such as sulfatides from m/z 700-1100 and chloride adductsof ceramides (Cer) from m/z 500-700, and glycerophospholipids (GL) suchas glycerophosphoinositols (PI), glycerophosphoethanolamines (PE),glycerophosphoserines (PS) and doubly charged cardiolipins (CL) from m/z700-1100. In the higher mass range from m/z 1100-1800, GL dimers andsingly charged CL were observed. A variety of peaks tentativelyidentified as small metabolites including glutamine at m/z 145.061,glutamate at m/z 146.045, N-acetylaspartic acid at m/z 174.041 andchloride adduct of hexose at m/z 215.033 were detected in lower massrange from m/z 120-250, based on high mass accuracy measurements andtandem mass spectrometry data (Table 1). Importantly, the negative ionmode mass spectra obtained from the grey matter from different tissuesections of the same mouse brain were reproducible (RSD=9.3%, n=9),comparable to what reported using the same method for DESI-MSI(RSD=8.0%, n=5) In the positive ion mode, the mass spectra obtainedpresented high relative abundances of commonly observed molecularspecies identified as diacylglycerols (DG), PE, andglycerophosphocholine (PC) (FIG. 18 ). Tentative assignments wereperformed using high mass accuracy measurements, as well as tandem MSanalysis when adequate intensity of fragment ions was achieved forstructural interpretation. Mass errors and the m/z of fragment ionsobtained by tandem MS experiments are described for all the speciesidentified throughout the manuscript in Tables 1, 2, 3, 4 and 5. Notethat isomerism of the double bonds in the FA chains of complex lipidscomplicates precise structural assignment, which is why FA chains aretentatively assigned for lipid species (Dill et al., Analytical andBioanalytical Chemistry, 12, 2011).

The MasSpec Pen spectrum was compared with the DESI spectrum which wasacquired under similar MS parameters but using the commonly appliedacetonitrile and dimethylformamide solvent system due to its highefficiency for extracting lipids from biological tissue. Interestingly,in the negative ion mode, the spectrum from MasSpec Pen using water asthe extraction solvent shared large amount of molecular species from m/z500 to m/z 1800 with the spectrum from DESI using ACN and DMF, withslightly higher ratios of PE lipids, such as PE (40:6) (m/z 790.539) andPE (38:4) (m/z 766.539). FIGS. 6A-B shows that PI (38:4) (m/z 885.550)and PS (38:6) (m/z 834.529) were the dominant peaks in both the spectrafrom MasSpec Pen and DESI. Moreover, in the spectra, a group of ionswith higher m/z were witnessed in the mass range from m/z 1500 to m/z1600, which were tentatively assigned to be singly charged cardiolipins(CL) and/or glycerophospholipid dimers.

Further analysis compared the molecular species detected in the negativeion mode with those observed in a DESI mass spectrum acquired from aserial tissue section of the same mouse brain using water as the solventand analogous experimental conditions. The mass spectra obtained usingthe MasSpec Pen and DESI were similar with a calculated cosinesimilarity of 0.9, sharing a large number of molecular species atcomparable relative abundances and signal-to-noise (S/N) ratios (FIG.6C). Other solvent systems including mixtures of water with ethanol atvarious ratios were also explored as solvent systems for the MasSpecPen. The mass spectra obtained presented similar lipid species to thoseobserved in the mass spectra obtained using pure water, with variationsin their relative abundances (FIG. 3B). Thus, to ensure fullbiocompatibility of the device, water was selected as the solvent forall the following MasSpec Pen experiments performed.

To evaluate the system performance, consecutive analysis was conductedon the same tissue section and different tissue sections anddemonstrated that the system is highly reproducible within samples andacross different samples.

Molecular Analysis of Human Cancer and Normal tissues sections. Ambientionization mass spectrometry has been extensively investigated formolecular diagnosis of human cancerous tissues. To test the capabilityof MasSpec Pen system described herein for differentiating the normaland tumorous samples, 62 human tissue samples of five different tissuetypes including breast, kidney, lymph node, thyroid and ovary, wereanalyzed. The mass spectra obtained in the negative ion mode using wateras solvent system for each tissue type showed molecular ions commonlyobserved by DESI-MS, with high relative abundances of metabolites andlipids. Principal component analysis (PCA) was employed to statisticallyevaluate the performance of MasSpec Pen in interspecific andintraspecific analyses of human specimen. It should be noted that thefirst three components, which all encompassed more than 85% of the totalvariance, are used in the present work. As can be seen in FIGS. 9A-B,normal thyroid and kidney tissues were well discriminated from thetumorous ones. Surprisingly, during the analysis of human tissuesections under negative ion mode, a series of multiply charged specieswere detected and were identified as thymosin β-4 by high mass accuracymeasurements and tandem mass spectrometry analysis (FIG. 7 ). Therepresentative spectra of each specimen are shown in FIG. 5 .Remarkably, the molecular profiles obtained from human normal thyroidand cancerous tissue shows distinct molecular patterns that arediagnostic of disease state. Similar results were obtained for all theother cancerous tissues analyzed.

The capability of the MasSpec Pen was tested to analyze 20 thin tissuesections of normal and tumor human breast (n=5 normal breast, n=5 breastductal carcinoma) and thyroid (n=5 normal thyroid, n=4 papillary thyroidcarcinoma, and n=1 follicular thyroid adenoma) tissues. The mass spectraobtained in the negative ion mode for each tissue type presented a richvariety of molecular ions commonly observed from human tissues byDESI-MSI, with high relative abundances of metabolites, fatty acids, andcomplex lipids. For example, the mass spectra obtained for papillarythyroid carcinoma tissue sections presented lipid species previouslyidentified as diagnostic markers by DESI-MSI (Zhang et al., CancerResearch, 76, 2016), including a variety of doubly-charged CL, and otherglycerophospholipids such as PI (38:4) (m/z 885.550), PI (36:4) (m/z857.518), PE (38:4) (m/z 766.539), and PE (36:2) (m/z 742.539) (Table2). A distinct mass spectral profile was obtained for normal thyroidtissue section, presenting high relative abundances of m/z 126.904,identified as iodine, m/z 145.050, identified as glutamine, m/z 175.024,identified as ascorbic acid, m/z 822.472, tentatively assigned toC₃₆H₇₈O₉N₃I, and m/z 885.551, identified as PI (38:4) (FIG. 8B).Interestingly, a series of multiply charged molecular ions at differentcharge states (z) including m/z 991.091 (z=−5), m/z 1239.113 (z=−4), andm/z 1652.484 (z=−3) was detected in the mass spectra obtained from alltissue sections analyzed. These ions were tentatively identified asdifferent charge states of the protein thymosin β-4 based on high massaccuracy measurements (FIG. 7 and Table 1). Notably, principal componentanalysis (PCA) performed on the data obtained from the human tissuesections analyzed showed separation between tumor and normal tissues(FIG. 9 ).

Molecular Analysis of Fresh Tissue Samples. The MasSpec Pen device wasdesigned to operate on fresh tissue samples independently of morphology.To test the device for fresh tissue analysis, fresh mouse brain tissuewas used in the beginning. No significant differences were observed inthe spectra obtained from mouse brain tissue sections or fresh braintissues. FIGS. 4A-4B show nearly identical mass spectrometric patternfrom mouse brain fresh tissue and tissue sections, which illustratesthat the extraction process from MasSpec Pen works similarly fordifferent sample preparation steps. Then, two types of fresh humanspecimens were further analyzed, thyroid gland and lymph node. Thespectra from normal and cancerous thyroid fresh tissue samples wereshown in FIG. 8 .

It should be noted that all the frozen specimens that were obtained fromtissue banks, had been well preserved under −80° C. in freezer and werethawed at room temperature before use. The data collected from freshhuman specimens were also processed by PCA. PCA of the spectra recordedshows a clear distinction between the normal and tumorous samples (FIGS.10A-10B). Therefore, it is established that MasSpec Pen could beemployed to differentiate fresh normal and diseased samples. It shouldbe noted that no damage to the tissue was observed due to the samplingprocess.

TABLE 1 Data obtained for the identification of selected negative ionmode molecular ions from mouse brain tissue. Main Fragment ProposedProposed Measured Theoretical Mass error ions upon Identificationformula m/z m/z (ppm) MS/MS^(a) Thymosin β-4 C₂₁₂H₃₅₀N₅₆O₇₈S₁ 991.091(−5) 991.090 (−5)  <1 (−5) NA 1239.113 (−4)  1239.114 (−4)   <1 (−4)1652.484 (−3)  1652.488 (−3)  2.4 (−3) ST t42:1  C₄₈H₉₂NO₁₂S 906.634906.635 −1.1 NA PI 38:4 C₄₇H₈₂O₁₃P 885.550 885.550 <1 152.995, 241.011,283.264, 303.233, 419.257, 581.309 PS 40:6 C₄₆H₇₇NO₁₀P 834.529 834.529<1 152.994, 283.264, 327.233, 419.256, 437.267, 747.497 PE 40:6C₄₅H₇₇NO₈P 790.539 790.539 <1 283.243, 283.264, 327.232, 480.309 38:4C₄₃H₇₇NO₈P 766.539 766.539 0 259.243, 283.263, 303.232, 480.309 P-38:6  C₄₃H₇₃NO₇P 746.513 746.513 <1 283.243, 327.232, 436.282 O-36:3 C₄₁H₇₇NO₇P 726.545 726.544 1.4 140.010, 152.994, 281.248, 444.288,462.299 P-36:4   C₄₁H₇₃NO₇P 722.513 722.513 <1 152.994, 259.243,303.233, 418.273, 436.283 Cer 36:1 C₃₆H₇₁NO₃Cl 600.513 600.513 <1 NA FA22:6 C₂₂H₃₁O₂ 327.233 327.233 <1 229.195, 283.243, 309.174 20:4 C₂₀H₃₁O₂303.233 303.233 <1 205.195, 259.243, 284.991 18:0 C₁₈H₃₅O₂ 283.264283.264 <1 265.130 16:0 C₁₆H₃₁O₂ 255.233 255.233 <1 237.043 N- C₆H₈NO₅174.040 174.041 −5.7 58.028, Acetylaspartic 88.039, acid 130.049 hexoseC₆H₁₂O₆Cl 215.033 215.034 −4.7 NA glutamate C₅H₈NO₄ 146.045 146.046 −6.8102.054, 128.034 Glutamine C₅H₉N₂O₃ 145.061 145.062 −6.9 127.050,128.034 ^(a)NA (not available) means that only high mass accuracy wasused for tentative ion identification.

TABLE 2 Data obtained for the identification of selected negative ionmode molecular ions from human thyroid tissue. Main Fragment ProposedProposed Measured Theoretical Mass error ions upon Identificationformula m/z m/z (ppm) MS/MS^(a) PI 40:5 C₄₉H₈₄O₁₃P 911.566 911.566 <1 NA38:4 C₄₇H₈₂O₁₃P 885.550 885.550 <1 152.994, 223.006, 241.011, 283.264,303.233, 419.256, 581.310 36:4 C₄₅H₇₈O₁₃P 857.518 857.518 <1 152.994,241.011, 279.233, 415.226, 577.278 34:1 C₄₅H₈₀O₁₃P 835.534 835.534 <1152.994, 241.011, 255.232, 391.226, 553.277 PE 38:4 C₄₃H₇₇NO₈P 766.539766.539 <1 140.010, 152.995, 259.243, 283.264, 303.233, 480.309 36:2C₄₁H₇₇NO₈P 742.539 742.540 −1.3 140.010, 152.994, 281.248 P-36:4  C₄₁H₇₃NO₇P 722.513 722.513 <1 140.010, 196.037, 259.243, 303.233,418.270, 436.283 CL 74:7 C₈₃H₁₄₆O₁₇P₂ 738.502 738.502 <1 NA 72:8C₈₁H₁₄₀O₁₇P₂ 723.479 723.479 <1 NA Cer 34:1 C₃₄H₆₇NO₃Cl 572.481 572.482−1.7 NA FA 20:4 C₂₀H₃₁O₂ 303.233 303.233 <1 205.195, 259.243, 284.99218:0 C₁₈H₃₅O₂ 283.265 283.264 3.5 265.130 18:1 C₁₈H₃₃O₂ 281.250 281.2493.6 NA 18:2 C₁₈H₃₁O₂ 279.234 279.233 3.6 261.222 16:0 C₁₈H₃₁O₂ 255.233255.233 <1 NA Ascorbic C₆H₇O₆ 175.024 175.025 −5.7 87.007, acid 115.002Glutamine C₅H₉N₂O₃ 145.050 145.062 −8.3 NA I- 126.904 126.905 −7.9 NA^(a)NA (not available) means that only high mass accuracy was used fortentative ion identification.

TABLE 3 Data obtained for the identification of selected negative ionmode molecular ions from human ovarian tissue. Main Fragment ProposedProposed Measured Theoretical Mass error ions upon Identificationformula m/z m/z (ppm) MS/MS^(a) PI 40:4 C₄₉H₈₆O₁₃P 913.581 913.581 <1223.000, 241.011, 283.264, 331.264, 419.257, 581.309 38:4 C₄₇H₈₂O₁₃P885.549 885.550 −1.1 152.994, 223.000, 241.011, 283.264, 303.233,419.256, 439.225, 581.309 36:1 C₄₅H₈₄O₁₃P 863.565 863.566 −1.2 152.995,241.011, 281.248, 283.264, 419.256 34:1 C₄₃H₈₀O₁₃P 835.534 835.534 <1152.994, 223.000, 241.011, 255.233, 281.248, 391.225, 553.278 PS 38:3C₄₄H₇₉NO₁₀P 812.544 812.545 −1.2 152.994, 283.264, 305.248, 419.256,437.266, 725.514 36:1 C₄₂H₇₉NO₁₀P 788.545 788.545 <1 281.248, 283.264,417.242, 419.256, 437.268, 701.512 PE 38:4 C₄₃H₈₀O₁₃P 766.539 766.539 <1259.243, 283.264, 303.233, 480.309 O-38:5  C₄₃H₇₇NO₇P 750.544 750.544 <1259.243, 303.233, 446.303, 464.313 P-35:4   C₄₁H₇₃NO₇P 722.512 722.513−1.4 259.243, 303.233, 418.273, 436.283 FA 16:0 C₁₆H₃₁O₂ 255.232 255.233−3.9 NA Ascorbic acid C₆H₇O₆ 175.024 175.024 <1 87.007, 115.002 ^(a)NA(not available) means that only high mass accuracy was used fortentative ion identification.

TABLE 4 Data obtained for the identification of selected negative ionmode molecular ions from human lung tissue. Main Mass Fragment ProposedProposed Measured Theoretical error ions upon Identification formula m/zm/z (ppm) MS/MS^(a) PI 40:4 C₄₉H₈₆O₁₃P 913.580 913.581 −1.1 152.994,223.000, 241.010, 283.264, 331.264, 419.256, 581.311 38:4 C₄₇H₈₂O₁₃P885.550 885.550 <1 152.994, 223.000, 241.011, 283.264, 303.233, 419.256,581.311 36:1 C₄₅H₈₄O₁₃P 863.565 863.566 −1.2 152.994, 241.011, 281.248,283.264, 419.256, 581.311 36:2 C₄₅H₈₂O₁₃P 861.548 861.549 −1.2 152.994,223.000, 241.011, 281.256, 417.241 PG 36:2 C₄₂H₇₈O₁₀P 773.542 773.534 10152.994, 281.256, 417.241, 491.278, 509.288 34:1 C₄₀H₇₆O₁₀P 747.514747.517 −4.0 152.994, 255.233, 281.256, 391.226, 417.241, 491.277 PE38:4 C₄₃H₇₇NO₈P 766.535 766.539 −5.2 140.010, 283.256, 303.233, 480.309,36:1 C₄₁H₇₉NO₈P 744.552 744.555 −4.0 140.011, 281.256, 283.264, 480.307P-38:4   C₄₃H₇₇NO₇P 750.534 750.544 −13 259.243, 303.233, 464.314P-36:4   C₄₁H₇₃NO₇P 722.511 722.513 −2.8 259.243, 303.233, 418.273,436.283 O-34:2  C₃₉H₇₅NO₇P 700.527 700.529 −2.9 NA Cer 34:1 C₃₄H₆₇NO₃Cl572.479 572.482 −5.2 NA FA 18:1 C₁₈H₃₃O₂ 281.249 281.249 <1 NA AscorbicAcid C₆H₇O₆ 175.023 175.024 −5.7 115.002 ^(a)NA (not available) meansthat only high mass accuracy was used for tentative ion identification.

TABLE 5 Data obtained for the identification of selected negative ionmode molecular ions from human breast tissue. Main Proposed MassFragment Identifi- Proposed Measured Theoretical error ions upon cationformula m/z m/z (ppm) MS/MS^(a) PI 38:4 C₄₇H₈₂O₁₃P 885.550 885.550 <1152.994, 223.000, 241.011, 283.264, 303.233, 419.257, 581.310, 599.31936:1 C₄₅H₈₄O₁₃P 863.565 863.566 −1.2 152.994, 223.000, 241.011, 281.248,283.264, 419.256, 581.309 PG 36:2 C₄₂H₇₈O₁₀P 773.542 773.534 10 152.994,281.248, 417.240, 491.276 FA 20:4 C₂₀H₃₁O₂ 303.233 303.233 <1 205.195,259.243, 284.991 18:1 C₁₈H₃₃O₂ 281.249 281.249 <1 NA ^(a)NA (notavailable) means that only high mass accuracy was used for tentative ionidentification.

TABLE 6 Patient demographics of the 253 human tissue samples used inthis study. Number of Number of patients by patients by race Median age,Age range, gender (White, Black, Patient Diagnosis Years Years (male,female) Asian, Unknown) Breast Normal 47 24-76  (0, 29) (21, 7, 1, 0)Cancer 58 41-75  (2, 14) (10, 2, 4, 0) Lung Normal 57 12-82 (33, 14)(35, 12, 0, 0) Cancer 66 22-84 (25, 23) (35, 7, 0, 6) Ovary Normal 5031-80  (0, 29) (22, 7, 0, 0) Cancer 62 30-83  (0, 28) (25, 2, 0, 1)Thyroid Normal 40 18-80 (10, 17) (18, 7, 0, 2) Tumor 49 16-81 (12, 17)(21, 4, 0, 4)

Materials and Methods

Mass Spectrometer. Q Exactive Hybrid Quadrupole-Orbitrap massspectrometer (Thermo Scientific, San Jose, Calif.) was used. Full-scanwas carried out at the range of m/z 120-1800, and the other massspectrometric parameters were listed as follows: resolving power 140000, micro scan 2, maximum injection time 300 ms, capillary temperature350° C. and S-lens RF level 100.

Biological Tissues. Wild-type mouse brains were purchased fromBioreclamation IVT. 62 frozen human tissue specimens including breast,thyroid, lymph node, ovarian, and kidney were obtained from CooperativeHuman Tissue Network and Baylor College Tissue Bank. Samples were storedin a −80° C. freezer. Tissue slides were sectioned at 16 μm using aCryoStar™ NX50 cryostat. Frozen tissue specimen were thawed under roomtemperature before use.

Statistical Analysis. IBM SPSS Statistics 22.0 (IBM Corporation, Armonk,N.Y., USA) was used to perform principal component analysis (PCA) toreveal patterns in the data. The analysis was performed directly usingthe raw data. The 10 peaks of the top relative intensities in the m/zrange of 700-900 were used for PCA. Typically, the first threecomponents, which all encompassed more than 85% of the total variance,are used in the present results.

Example 3—System Automation for Handheld and Laparoscopic Use

Because all the materials (PDMS and PTFE) and solvent (only water) usedin the MasSpec Pen design are biologically compatible, the system has ahigh potential to be used in surgery in handheld way for real-timeanalysis. More than that, due to the small dimension of the device, itcan even be integrated to a robotic surgical system, such as the DaVinci surgical system through an accessory port or one of its roboticarms. Several regions of the human body cavity can be quickly sampledduring surgery, and analyzed by using a database of molecular signaturesand machine learning algorithms. Therefore, the diagnosing results maybe provided in real time for each sampled region. This system can bebroadly used in a wide variety of oncological and other surgicalinterventions (such as endometriosis) for which real-timecharacterization and diagnosis of tissues are needed.

Example 4—Predictive Analysis of Tissue Samples

The MasSpec Pen design was used to analyze tissue samples from patientswith breast cancer, lung cancer, ovarian cancer, or thyroid cancer alongwith normal tissue samples. Before these samples were analyzed, thesamples were processed by rounding the mass to charge ratio (m/z) to thenearest 0.01 and normalizing the total ion chromatogram (TIC). Allbackground m/z peaks and those peaks which appeared in less than 10% ofthe patient samples were also removed. The full mass range was used inthe analysis. The trained classifier was a lasso logistic regressionmodel. For tissue samples in which the presence of cancer was beinganalyzed, the overall performance results for all classifiers is shownin Table 7. The overall results has an accuracy of 96.3%, sensitivity of96.4%, and specificity of 96.2%.

TABLE 7 Tissue Sample Prediction Relative to True Determination of AllNormal vs All Cancer* Predicted Normal Cancer True Normal 127 5 Cancer 4106 *not including Benign Thyroid

For the tissue samples in which the presence of lung cancer was beinganalyzed, Table 8 shows the mass to charge values (m/z) used in thedifferentiation of the tissue samples along with the associatedcoefficient for that particular value.

TABLE 8 Lung Cancer Mass to Charge Values (m/z) and Coefficients forNormal Lung vs Lung Cancer m/z Coefficient 175.02 32.51042 187.01492.94937 201.04 324.19856 215.03 −134.54101 313.16 −711.31964 330.9831.73486 332.90 −49.54229 357.10 −903.32504 409.23 218.36836 615.17−418.02900 722.51 42.39442 744.55 780.14488 747.52 −248.52283 748.52−494.98929 771.52 6.80739 773.53 −292.30917 863.57 −722.21921 885.55703.46083 886.55 8.82125

Table 9 shows the analysis rate and the classification of each samplewith the true (histological) determination in rows and the predictedvalue in the columns. Of the cancer tissue samples, the samples wereidentified with an accuracy of 96.8%, a sensitivity of 97.9%,specificity of 95.7% and AUC of 0.97.

TABLE 9 Tissue Sample Prediction Relative to True Determination for LungCancer Predicted Prop. Normal Cancer correct True Normal 45 2 0.957Cancer 1 47 0.979

Similar analysis was performed for normal lung vs adenocarcinoma samplesas shown in Table 10 and Table 11. The samples were identified with92.2% accuracy, 88.2% sensitivity, 93.6% specificity, and AUC of 0.98.

TABLE 10 Lung Cancer Mass to Charge Values (m/z) and Coefficients forNormal Lung vs Adenocarcinoma m/z Coefficient 175.02 78.79492 201.04113.95819 747.52 −134.59620 773.53 −17.30482 885.55 205.16262

TABLE 11 Tissue Sample Prediction Relative to True Determination forLung Squamous Cell Carcinoma Predicted Prop. Normal Cancer Correct TrueNormal 44 3 0.936 Cancer 2 15 0.882

Similar analysis was performed for normal lung vs squamous samples asshown in Table 12 and Table 13. The samples were identified with 93.8%accuracy, 88.2% sensitivity, 95.7% specificity, and AUC of 0.93.

TABLE 12 Lung Cancer Mass to Charge Values (m/z) and Coefficients forNormal Lung vs Squamous Cell Lung Cancer m/z Coefficient 201.04203.209288 306.08 2.171805 747.52 −83.325218 773.53 −101.591552 861.55−22.995934 885.55 248.475559

TABLE 13 Tissue Sample Prediction Relative to True Determination forLung Cancer Predicted Prop. Normal Cancer Correct True Normal 45 2 0.957Cancer 2 15 0.882

Similar, to the analysis carried out for lung cancer described above, asimilar analysis was carried out with ovarian, thyroid, and breastcancer and showing the respective m/z peaks and coefficients for eachset of samples. Ovarian cancer samples were detected with 94.7%accuracy, 100% sensitivity, 89.7% specificity, and AUC of 0.98. Thethyroid cancer samples were detected with 94.7% accuracy, 90.9%sensitivity, 96.3% specificity, and AUC of 0.93. Finally, breast cancersamples were detected with 95.6% accuracy, 87.5% sensitivity, 100%specificity, and AUC of 1.00.

TABLE 14 Ovarian Cancer Mass to Charge Values (m/z) and Coefficients m/zCoefficient 124.01 −0.39418349 175.02 −0.44099907 175.03 −0.65091248283.27 −0.19534503 313.16 0.13896620 341.27 −0.01845538

TABLE 15 Tissue Sample Prediction Relative to True Determination forOvarian Cancer Predicted Prop. Normal Cancer Correct Normal 26 3 0.897Cancer 0 28 1.000

TABLE 16 Thyroid Cancer Mass to Charge Values (m/z) and Coefficients forNormal Thyroid vs Benign Tumor m/z Coefficient 175.02 0.050122579 191.02−0.009462112 191.05 −0.354060964 283.27 −0.471995496 341.27 −0.151684619615.17 −0.208451792 822.47 −1.009896669 822.48 −1.045185471

TABLE 17 Tissue Sample Prediction Relative to True Determination forNormal Thyroid vs Benign Tumor Predicted Prop. Normal Cancer CorrectTrue Normal 26 1 0.963 Cancer 1 10 0.909

TABLE 18 Thyroid Cancer Mass to Charge Values (m/z) and Coefficients forNormal Thyroid vs Malignant Tumor m/z Coefficient 175.02 −0.13520642283.27 −0.41455282 341.27 −0.16730814 353.16 −0.06014487 432.20−0.31647335 433.21 −0.07291166 615.17 −0.61749889 822.47 −0.53746679822.48 −1.04230818

TABLE 19 Tissue Sample Prediction Relative to True Determination forNormal Thyroid vs Benign Tumor Predicted Prop. Normal Cancer CorrectTrue Normal 26 1 0.963 Cancer 1 10 0.909

TABLE 20 Thyroid Cancer Mass to Charge Values (m/z) and Coefficients forNormal Breast vs Breast Cancer m/z Coefficient 187.04 476.70006 268.80−190.32304 279.92 79.49933 283.27 −31.45926 341.27 −11.77054 345.16−154.78978 381.21 −68.13689 687.51 −39.13906 742.54 1771.27018 766.541663.80192

TABLE 21 Tissue Sample Prediction Relative to True Determination forNormal Breast vs Breast Cancer Predicted Prop. Normal Cancer CorrectTrue Normal 29 0 1.000 Cancer 2 14 0.875

Example 5—Spatial Resolution of the MasSpec Pen System

The spatial resolution of the MasSpec Pen system was tested anddetermined that higher spatial resolution could be determined using aspecific spot. Testing was carried out using white vs. grey matter in amouse brain. Shown in FIGS. 11A-11E show the portion of the brain testedwith the particular size of the spot. In particular, Sample Spot 1 showsthe spot was primarily comprised of gray matter

Example 6—Non-Destructive Molecular Analysis of Tissue Samples

The MasSpec Pen was designed to operate directly on tissue specimensindependently of tissue stiffness and morphology. The performance of theMasSpec Pen was tested to analyze soft tissue samples (0.1-5 g) fromdifferent organs including mouse brain and human breast, thyroid, lungand ovary tissues. Tissue analyses were performed in ambient conditionsthrough a simple one-step experiment, following the same automatedoperational steps described previously. The MasSpec Pen tip was gentlycontacted to the surface of the tissue sample for a period of 3 s whileextraction took place. The mass spectra obtained for a region of greymatter from the mouse brain was reproducible (RSD=4.6%, n=10) and highlysimilar to the mouse brain tissue section mass spectra (cosinesimilarity of 0.93) (FIG. 4 ), thus indicating that the extractionprocess at the tissue surface efficiently occurs independently on thetissue shape and rigidity. Similarly, MasSpec Pen analyses of humantissue samples provided rich molecular information, especially oftissues composed of epithelial and cancerous cells. Non-cancerous tissuespecimens that were mostly composed of soft connective tissue such asstroma provided less abundant mass spectral profiles. In particular,many of the normal breast cancer tissue samples analyzed presented fatcontent, which is immiscible with water and thus yielded less abundanttotal ion counts in the mass spectra when compared to breast cancertissues or normal breast cancer glands.

Visual and microscopic inspection of all the tissue samples afterMasSpec Pen analysis revealed no detectable damage to the tissue samplemorphology in the region probed. FIG. 15 shows optical images obtainedfrom a lung tissue sample prior, during and after the MasSpec Penanalysis. No observable damage to the tissue was seen at the regionanalyzed, while rich mass spectra profiles were obtained (FIG. 15 ).Note that the automated and time-controlled operational steps of theMasSpec Pen prevents tissue damage as the tissue is only exposed to thesmall water droplet and not to the vacuum used to transport the dropletfrom the reservoir to the mass spectrometer. Thus, these results provideevidence that the MasSpec Pen is a non-destructive approach to obtainrich molecular information from tissue samples.

Example 7—Molecular Diagnosis and Statistical Prediction of Cancer inHuman Tissues

It was next evaluated if the molecular information obtained from humantissue samples using the MasSpec Pen was diagnostic and predictive ofdisease state. A total of 253 human tissue specimens using the MasSpecPen, including 95 lung samples (47 normal and 48 cancer samplesincluding 17 adenocarcinoma, 17 squamous cell carcinoma, and 14 cancersamples of other histologic subtypes), 57 ovary samples (29 normal and28 HGSC), 57 thyroid samples (27 normal, 11 follicular thyroid adenomaand 18 papillary thyroid carcinoma), and 45 breast samples (29 normaland 16 ductal carcinoma) (FIG. 11 ). Patient demographic information isprovided in Table 6. After MasSpec Pen analysis, the region analyzed wasdemarcated and registered through a series of optical images. Then,parallel pieces of the samples were frozen, sectioned at the demarcatedregion, H&E stained and evaluated by histopathology to derive adiagnosis. Only samples with a predominant cell composition and cleardiagnosis were used to build molecular databases. The histologicallyvalidated mass spectra obtained for the cancerous samples presentedmolecular species identified as several lipids and metabolitespreviously described as potential disease markers using ambientionization MS techniques. For lung cancer tissue, characteristicmolecular markers such as m/z 863.565, identified as PI (36:1), m/z773.542, identified as PG (36:2), m/z 747.514, identified as PG (34:1),and fatty acids as m/z 281.249, identified as FA (18:1), were observed(FIG. 15 and Table 4). For normal lung, m/z 885.550, identified as PI(38:4), and m/z 744.552, identified as PE (36:1) were observed. The massspectra obtained for breast cancer tissue presented diagnostic lipidmarkers previously described by DESI-MSI (29, 30), including m/z885.550, identified as PI (38:4), m/z 863.565, identified as PI (36:1),m/z 773.542, identified as PG (36:2), and several FA such as m/z303.233, identified as FA (20:4), and m/z 281.249, identified as FA(18:1) (Table 5). PCA performed on the data obtained for all the 253human tissue samples analyzed showed separation between cancer andnormal tissues for each organ (FIG. 11 ).

To evaluate if the MasSpec Pen molecular signatures are predictive ofcancer and normal tissues, the Lasso method was applied to buildclassification models using the histologically validated mass spectraldatabase. The performance of the model was evaluated through aleave-one-patient-out cross-validation approach, and measured bysensitivity and specificity for cancer, as well as accuracy and AUC(Table 22). For breast cancer (n=45), 87.5% sensitivity, 100%specificity (AUC=1.0), an overall accuracy of 95.6% was achieved, whichis comparable to the results reported using DESI-MSI (98.2% accuracy,n=126) (Guenther et al., Cancer Research, 75, 2015)), the iKnife (95.5%accuracy, n=10) (Balog et al., Science Translational Medicine, 5, 2013),and MALDI imaging of lipids and proteins (94.1% accuracy, n=68) (31).For HGSC (n=57), 100% sensitivity, 89.7% specificity, and 94.7% accuracywas achieved (AUC=0.98), which is also similar to classification resultsobtained by DESI-MSI (97.1% accuracy, n=31) (Sans et al., CancerResearch, 2017). For lung cancer (n=956), 98.097.9% sensitivity, 95.7%specificity, and 96.89% accuracy was achieved (AUC=0.97). Whenpredicting based on lung cancer histologic subtypes, 93.8% and 92.2%accuracy was achieved for squamous cell carcinoma and adenocarcinoma,respectively. Thyroid tumor samples investigated included benignfollicular thyroid adenoma (FTA) and malignant papillary thyroidcarcinoma (PTC) samples. A classifier for each was built yielding 94.7%accuracy for FTA and 97.8% accuracy for PTC. Overall, 96.4% sensitivity,96.2% specificity and 96.3% accuracy was achieved for all the four typesof cancer investigated. These results demonstrate that the molecularinformation obtained from human tissue samples by the MasSpec Pen ishighly predictive of cancer. Further, the results indicate that thestatistical classifiers built on the molecular data acquired using theMasSpec Pen are robust and may be used in an automated approach forrapid clinical diagnosis of tissue samples.

TABLE 22 Description of the samples and results obtained using theMasSpec Pen. Pathological diagnosis, number of patient samples, and theLasso prediction sensitivity, specificity, accuracy, and area under thecurve obtained using a leave-one-out cross validation approach areshown. Pathologic Evaluation Number of Lasso Prediction Organ DiagnosisHistologic Type Patients Sensitivity Specificity Accuracy AUC BreastNormal 29 87.5% 100.0%  95.6% 1.00 Cancer Ductal Carcinoma 16 Lung^(a)Normal 47 98.0% 95.7% 96.9% 0.97 Cancer Adenocarcinoma 17 88.2% 93.6%92.2% 0.98 Squamous Cell 17 88.2% 95.7% 93.8% 0.93 Other 14 — — — —Ovary Normal 29 100.0%  89.7% 94.7% 0.98 Cancer High Grade Serous 28Thyroid^(b) Normal 27 — — — — Tumor Papillary Carcinoma 18 94.4% 100.0% 97.8% 0.99 Follicular Adenoma 11 90.9% 96.3% 94.7% 0.93 ^(a)Lassoprediction results for lung cancer are shown for normal versus allcancer tissues (first row), followed by normal versus lungadernocarcinoma (middle row) and normal versus squamous cell carcinoma(last row). ^(b)Lasso prediction results for thyroid cancer are shownfor normal versus malignant papillary carcinoma, and normal versusbenign follicular adenoma.

Example 8—Intra-Sample Analysis of Histologic Distinct and Cancer MarginTissue Regions

The ability of the MasSpec Pen to identify histologically distinctregions was evaluated in a single human tissue sample that containedregions of HGSC adjacent to normal ovarian stroma tissue. Fiveconsecutive spots in the tissue sample were analyzed using a MasSpec Penwith a 1.5 mm diameter, as demarcated in the optical image shown in FIG.14A. A tissue section of the sample including the regions analyzed bythe MasSpec Pen was subjected to H&E staining and evaluated byhistopathology. Spots 1 and 2 were diagnosed by expert pathologists asnormal stroma, while regions 4 and 5 were diagnosed as HGSC. Spot 3 wasin the margin between the cancer and normal stroma tissue regions,presenting ˜50% tumor tissue and ˜50% normal stroma tissue. FIG. 14Bshows the mass spectra obtained for spots 1, 3 and 5. The spectraobtained for spot 5, HGSC, presented characteristic lipid markersdetected in the HGSC tissues analyzed ex vivo to build our statisticalclassifier (Table 3). The mass spectra obtained for spot 1, diagnosed asnormal ovarian stroma tissue, presented less abundant molecules ions asalso observed for stroma tissues analyzed ex vivo. Spot 3 presentedmolecular profiles characteristic of HGSC with lower total abundance dueto the contribution of normal stroma tissue present within the regionanalyzed. The mass spectra obtained for the 5 spots were then evaluatedby our ovarian cancer molecular classifier as an independent validationset. Remarkably, this classified correctly predicted spots 1 and 2 asnormal, and 3, 4 and 5 as cancer (FIG. 14C). Similar results wereobtained for a different tissue sample with histologically distinctregions (FIG. 19 ). These results show that the molecular informationobtained by the MasSpec Pen can be used to detect cancer in marginalregions with mixed composition of normal and cancer cells.

Example 9—In Vivo Analysis of a Murine Model of Human Breast CancerDuring Surgery

The MasSpec Pen was designed with biocompatible materials to ensure fullcompatibility as an in vivo molecular diagnostic tool. The MasSpec Penwas tested for in vivo tissue analysis using a murine model of humanbreast cancer. BT474 HER2+ breast cancer cells were implantedsubcutaneously in nude athymic mice (n=3). The tumors were grown to anaverage of 250 mm³ over a period of 4 weeks. All surgical and MasSpecPen analysis procedures were performed under anesthesia. A surgicalblade was used to open a flap of skin surrounding the tumor, and thenthe skin flap was sharply dissected from the surface of the tumor. Theexposed tumor was then analyzed using the MasSpec Pen following the sameautomated experimental steps described previously. FIG. 16A shows anoptical image of the animal under anesthesia prior to initiation ofsurgery, before analysis (and after surgical removal of the skin),during the MasSpec Pen analysis, and after the analysis. Several tissueregions were analyzed for each animal investigated, including multiplepositions of the top of the tumor, the core of the tumor after partialtumor resection, as well as adjacent normal soft connective tissue. Themass spectra obtained for the tumor regions presented many molecularspecies observed in human breast tissue, with a clearly distinctiveprofile from what was obtained for adjacent normal soft connectivetissue regions (FIG. 16B). Using optical microscopy, no observablemacroscopic or microscopic damage to the tissue regions analyzed weredetected due to MasSpec Pen analyses, as evidenced by the optical imagesobtained of H&E stained tissue sections (FIG. 20 ). Further, no apparenteffects to the health of the animals were observed due to the MasSpecPen analysis during surgery. After in vivo analysis, freshly excisedtumor specimens were also analyzed ex vivo, yielding mass spectra withcommon lipid species to those observed in the in vivo analysis despitevariations in relative abundances, which are likely due to there-analysis process of the same tissue region (FIG. 21 ). These resultssuggest that the MasSpec Pen is suitable for in vivo molecularevaluation and cancer diagnosis.

Example 10—Materials and Methods

Study design: The objective of this study was to evaluate the potentialof a new mass spectrometry-based probe to non-destructively analyze anddiagnose cancer in human tissue samples. In this study, the molecularprofiles of human tissue samples obtained from 282 patients includingnormal and cancer breast, lung, thyroid, and ovary tissues wereinvestigated. All patient samples were obtained from the CooperativeHuman Tissue Network (CHTN), Asterand Biosciences (Detroit, Mich.), theMD Anderson Tissue Bank, and the Baylor College of Medicine Tissue Bank,under approved Institutional Review Board (IRB) protocol. The massspectra obtained using the MasSpec Pen in tissue samples werenormalized, background subtracted and analyzed using a statisticaltechnique to build classification models. Expert, board-certifiedpathologists (J. L, W. Y, and N. C) evaluated H&E stained tissuesections obtained from the tissue samples analyzed. The pathologistswere blind to any information about the acquisition from massspectrometry analysis. Samples were excluded from statistical analysisif they were determined by the pathologist to have substantialheterogeneity in cell composition, which included 28 samples. The invivo animal model experiments were conducted under approvedInstitutional Animal Care and Use Committee (IACUC) protocol.

Design and Engineering of the MasSpec Pen: A 3D printer (Model uPrint SEplus) was used to print the key component—PDMS (Dow Corning, Midland,Mich., USA) probe tip. The pen tips were fabricated by casting anelastomer from a negative mold and then dissolving the mold away. Thenegative molds were designed using SolidWorks computer aided design(CAD) software and then fused deposition modeled with the 3D printerusing ABS plastic (Stratasys, Eden Prairie, Minn., USA) and solublesupport material. The parts were then washed to remove support material,using a support cleaning apparatus (SCA-1200HT, SCA) and solvent(EcoWorks) at 70° C. for 24 hrs or until support material was fullydissolved. For the casting, a mixture of PDMS elastomer base and curingagent (Sylgard 184, Dow Corning) were prepared in a weight ratio of10:1, respectively. The mixture was poured into the 3-D printed molds,cured in an oven (10GCE-LT, Quincy Lab) at 74° C. for 1 h, and thenplaced in a closed container with acetone (Fisher Scientific, Waltham,Mass., USA) to dissolve. The final washing step had the tips sonicatedin acetone to remove any remaining ABS. PTFE tubing (ID 1/32 inch, OD1/16 inch, Cole-Parmer, Vernon Hills, Ill., USA) was directly insertedinto the probe tip for experiments.

Data acquisition: All experiments were performed on a Q Exactive hybridQuadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, SanJose, Calif.). Full-scan was carried out at the range of m/z 120-1800,using resolving power 140,000, capillary temperature of 350° C. andS-lens RF level of 100. Wild-type mouse brain were purchased fromBioreclamationIVT (Westbury, N.Y.). A total of 282 human tissuespecimens including breast, thyroid, ovary, and lung were obtainedfrozen and stored in a −80° C. freezer until analysis, when they werethawed in room temperature. The tissues were placed in a surface andanalyzed by the MasSpec Pen using the experimental steps described.After experiments, the tissue regions analyzed were annotated, frozen,and 16 μm tissue sections prepared using a CryoStar™ NX50 cryostat.Additional tissue sections at different regions of the tissue piece wereobtained for MS analysis. Tissue sections were kept frozen untilanalysis, when they were in room temperature and analyzed by the MasSpecPen. Tissue sections were then H&E stained and evaluated byhistopathology. The pathologic diagnosis was used as the reference forour molecular database.

In Vivo Experiments: In vivo experiments were performed during surgicalresection of tumors using murine animal models while the mice were underanesthesia (2% isoflurane, 98% O₂). BT474 HER2+ cells were grown inimproved minimal essential medium (IMEM, Invitrogen, Carlsbad, Calif.)supplemented with 10% FBS, 1% L-glutamine, and 1% insulin, to 80-90%confluency in 5% O₂ and 37° C. Cells were counted via hemocytometer andtrypan blue dye exclusion. Nude athymic female mice (N=3) weresubcutaneously implanted with a 0.72 mg, 60-day release, 17β-estradiolpellet (Innovative Research of America, Sarasota, Fla.) in the nape ofthe neck. Approximately 24 hours later, BT474 breast cancer cells (10⁷)in serum-free IMEM media with 20% growth factor-reduced Matrigel wereinjected subcutaneously into the right flank of the mouse (totalinjection of 100 μL). Tumors were monitored weekly for growth until theyreached 0.7-1.0 cm in diameter (average of 250 mm³). At that time point,all surgical procedures were performed while the mice were underanesthesia (2% isoflurane, 98% O₂). A surgical blade was used to open aflap of skin, leaving an estimated 1-2 cm of space around the tumors,and then the skin flap was dissected from the surface of the tumor. Theskin was flapped to expose the tumor and adjacent normal tissues, whichwere analyzed in several regions using the MasSpec Pen. Pieces of thetumor were then resected using a scalpel and analyzed ex vivo. Tumortissue regions analyzed by the MasSpec pen were annotated, flash frozen,sectioned, and subjected to H&E staining for diagnosis.

Statistical Analysis: Averages of three mass spectra obtained duringeach 10 seconds MasSpec Pen analysis were used to build moleculardatabases. The Xcalibur raw data was converted to Microsoft Excelspreadsheet format. The full mass range of the spectra were partitionedinto bins by rounding m/z values to the nearest hundredth. All massspectra were first normalized according to total ion count (TIC) or tothe absolute intensity of m/z 885.55, to account for slight fluctuationsin signal intensities that may occur between experiments. Then,background peaks as well as peaks not appearing in at least 10% of thesamples analyzed were excluded to reduce random noise.

For each tissue section (breast or thyroid), four representative massspectra for each tissue section analyzed were imported to metaboanalyst(http://www.metaboanalyst.ca/) for principal component analysis (PCA)using the website built-in function. Score plots and loading plots weregenerated through the website for each tissue type. For each soft tissuesample type (breast, thyroid, lung, and ovary), the data was imported toR programming language. PCA was performed by centering the pre-processeddata to mean zero and computing principal components using the prcompfunction in R. The first three principal components were visualized withthe rg1 and pca3d packages for R. For tissue classification, the Lassomethod was applied using the glmnet package in the CRAN R languagelibrary. Models generated using the Lasso are simpler to interpret thanother regularization methods, as it yields “sparse” models, that is,models that involve only a subset of the features. A mathematical weightfor each statistically informative feature is calculated by the Lassodepending on the importance that the mass spectral feature has incharacterizing a certain class (cancer versus normal, or a cancersubtype versus normal). Classification was performed using aleave-one-out cross-validation approach to assess the predictiveaccuracy within the training set. Performance of trained classifiers wasmeasured by sensitivity, specificity, accuracy, and AUC.

All of the methods disclosed and claimed herein can be made and executedwithout undue experimentation in light of the present disclosure. Whilethe compositions and methods of this invention have been described interms of preferred embodiments, it will be apparent to those of skill inthe art that variations may be applied to the methods and in the stepsor in the sequence of steps of the method described herein withoutdeparting from the concept, spirit and scope of the invention. Morespecifically, it will be apparent that certain agents which are bothchemically and physiologically related may be substituted for the agentsdescribed herein while the same or similar results would be achieved.All such similar substitutes and modifications apparent to those skilledin the art are deemed to be within the spirit, scope and concept of theinvention as defined by the appended claims.

What is claimed is:
 1. A method for assessing tissue samples from asubject, the method comprising: (a) applying a fixed or discrete volumeof a solvent to a tissue site in the subject; (b) collecting the appliedsolvent to obtain a liquid sample; (c) subjecting the liquid sample tomass spectrometry analysis, thereby obtaining a mass spectrometryprofile comprising a plurality of mass-to-charge (m/z) ratios; and (d)characterizing the liquid sample based on the mass spectrometry profile;wherein characterizing the liquid sample comprises determining whetherthe tissue site comprises: normal lung, breast, ovarian, or thyroidcells; benign lung, breast, ovarian, or thyroid cells; or cancerouslung, breast, ovarian, or thyroid cells; wherein when the profilecomprises at least 5 mass-to-charge (m/z) ratios selected from the groupconsisting of 175.02, 187.01, 201.04, 215.03, 306.08, 313.16, 330.98,332.90, 357.10, 409.23, 615.17, 722.51, 744.55, 747.52, 748.52, 771.52,773.53, 861.55, 863.57, 885.55, and 886.55, then the tissue site isidentified as comprising cancerous lung cells; wherein when the profilecomprises at least 3 mass-to-charge (m/z) ratios selected from the groupconsisting of 124.01, 175.02, 175.03, 283.27, 313.16, and 341.27, thenthe tissue site is identified as comprising cancerous ovarian cells;wherein when the profile comprises at least 5 mass-to-charge (m/z)ratios selected from the group consisting of 175.02, 191.02, 191.05,283.27, 341.27, 353.16, 432.20, 433.21, 615.17, 822.47, and 822.48, thenthe tissue site is identified as comprising cancerous thyroid cells; andwhen the profile comprises at least 5 mass-to-charge (m/z) ratiosselected from the group consisting of 187.04, 268.80, 279.92, 283.27,341.27, 345.16, 381.21, 687.51, 742.54, and 766.54, then the sample isidentified as comprising cancerous breast cells.
 2. The method of claim1, wherein the fixed or discrete volume of a solvent is applied as adroplet.
 3. The method of claim 1, wherein the fixed or discrete volumeof a solvent is applied at using a pressure of less than 100 psig. 4.The method of claim 1, wherein the fixed or discrete volume of a solventis applied at using a mechanical pump to move the solvent through asolvent conduit.
 5. The method of claim 1, wherein collecting theapplied solvent comprises applying a negative pressure to pull thesample into a collection conduit and/or applying a gas pressure to pushthe sample into a collection conduit.
 6. The method of claim 5, whereinthe solvent is applied through a solvent conduit that is separate fromthe collection conduit.
 7. The method of claim 6, wherein the gaspressure is applied through a gas conduit that is separate from thesolvent conduit and the collection conduit.
 8. The method of claim 1,wherein the method produces no detectable physical damage to the tissue.9. The method of claim 1, wherein the solvent comprises water, ethanol,or a combination thereof.
 10. The method of claim 1, wherein thediscrete volume of solvent is between about 0.1 and 100 μL.
 11. Themethod of claim 1, wherein collecting the applied solvent is between 0.1and 30 seconds after the applying step.
 12. The method of claim 1,further comprising collecting a plurality liquid samples from aplurality of tissue sites.
 13. The method of claim 12, wherein theliquid samples are collected with a probe and wherein the probe iswashed between collection of the different samples; wherein the probe isdisposable and is changed between collection of the different samples;or wherein the probe comprises a collection tip and further comprisingejecting the collection tip from the probe after the liquid samples arecollected.
 14. The method of claim 1, further defined as anintraoperative method.
 15. The method of claim 14, further comprisingresecting tissue sites that are identified to include cancerous lung,breast, ovarian, or thyroid cells.
 16. The method of claim 1, whereinthe liquid sample is obtained from the tissue site in vivo.
 17. Themethod of claim 1, wherein the liquid sample is obtained from the tissuesite ex vivo.